These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 26808133)

  • 1. Application of Targeted Next-generation Sequencing, TruSeq Custom Amplicon Assay for Molecular Pathology Diagnostics on Formalin-fixed and Paraffin-embedded Samples.
    Csernák E; Molnár J; Tusnády GE; Tóth E
    Appl Immunohistochem Mol Morphol; 2017 Aug; 25(7):460-466. PubMed ID: 26808133
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Amplicon-Based Targeted Next-Generation Sequencing of Formalin-Fixed, Paraffin-Embedded Tissue.
    Strengman E; Barendrecht-Smouter FAS; de Voijs C; de Vree P; Nijman IJ; de Leng WWJ
    Methods Mol Biol; 2019; 1908():1-17. PubMed ID: 30649717
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sequence artefacts in a prospective series of formalin-fixed tumours tested for mutations in hotspot regions by massively parallel sequencing.
    Wong SQ; Li J; Tan AY; Vedururu R; Pang JM; Do H; Ellul J; Doig K; Bell A; MacArthur GA; Fox SB; Thomas DM; Fellowes A; Parisot JP; Dobrovic A;
    BMC Med Genomics; 2014 May; 7():23. PubMed ID: 24885028
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Performance of amplicon-based next generation DNA sequencing for diagnostic gene mutation profiling in oncopathology.
    Sie D; Snijders PJ; Meijer GA; Doeleman MW; van Moorsel MI; van Essen HF; Eijk PP; Grünberg K; van Grieken NC; Thunnissen E; Verheul HM; Smit EF; Ylstra B; Heideman DA
    Cell Oncol (Dordr); 2014 Oct; 37(5):353-61. PubMed ID: 25209392
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PIK3CA mutation is a favorable prognostic factor in esophageal cancer: molecular profile by next-generation sequencing using surgically resected formalin-fixed, paraffin-embedded tissue.
    Yokota T; Serizawa M; Hosokawa A; Kusafuka K; Mori K; Sugiyama T; Tsubosa Y; Koh Y
    BMC Cancer; 2018 Aug; 18(1):826. PubMed ID: 30115035
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted Next Generation Sequencing as a Reliable Diagnostic Assay for the Detection of Somatic Mutations in Tumours Using Minimal DNA Amounts from Formalin Fixed Paraffin Embedded Material.
    de Leng WW; Gadellaa-van Hooijdonk CG; Barendregt-Smouter FA; Koudijs MJ; Nijman I; Hinrichs JW; Cuppen E; van Lieshout S; Loberg RD; de Jonge M; Voest EE; de Weger RA; Steeghs N; Langenberg MH; Sleijfer S; Willems SM; Lolkema MP
    PLoS One; 2016; 11(2):e0149405. PubMed ID: 26919633
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The efficacy of uracil DNA glycosylase pretreatment in amplicon-based massively parallel sequencing with DNA extracted from archived formalin-fixed paraffin-embedded esophageal cancer tissues.
    Serizawa M; Yokota T; Hosokawa A; Kusafuka K; Sugiyama T; Tsubosa Y; Yasui H; Nakajima T; Koh Y
    Cancer Genet; 2015 Sep; 208(9):415-27. PubMed ID: 26194062
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Next-generation sequencing of formalin-fixed, paraffin-embedded tumor biopsies: navigating the perils of old and new technology to advance cancer diagnosis.
    Latham GJ
    Expert Rev Mol Diagn; 2013 Nov; 13(8):769-72. PubMed ID: 24117229
    [No Abstract]   [Full Text] [Related]  

  • 9. Whole exome sequencing (WES) on formalin-fixed, paraffin-embedded (FFPE) tumor tissue in gastrointestinal stromal tumors (GIST).
    Astolfi A; Urbini M; Indio V; Nannini M; Genovese CG; Santini D; Saponara M; Mandrioli A; Ercolani G; Brandi G; Biasco G; Pantaleo MA
    BMC Genomics; 2015 Nov; 16():892. PubMed ID: 26531060
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HaloPlex Targeted Resequencing for Mutation Detection in Clinical Formalin-Fixed, Paraffin-Embedded Tumor Samples.
    Moens LN; Falk-Sörqvist E; Ljungström V; Mattsson J; Sundström M; La Fleur L; Mathot L; Micke P; Nilsson M; Botling J
    J Mol Diagn; 2015 Nov; 17(6):729-39. PubMed ID: 26354930
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship between formalin reagent and success rate of targeted sequencing analysis using formalin fixed paraffin embedded tissues.
    Amemiya K; Hirotsu Y; Oyama T; Omata M
    Clin Chim Acta; 2019 Jan; 488():129-134. PubMed ID: 30395866
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TumorNext: A comprehensive tumor profiling assay that incorporates high resolution copy number analysis and germline status to improve testing accuracy.
    Gray PN; Vuong H; Tsai P; Lu HM; Mu W; Hsuan V; Hoo J; Shah S; Uyeda L; Fox S; Patel H; Janicek M; Brown S; Dobrea L; Wagman L; Plimack E; Mehra R; Golemis EA; Bilusic M; Zibelman M; Elliott A
    Oncotarget; 2016 Oct; 7(42):68206-68228. PubMed ID: 27626691
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reducing sequence artifacts in amplicon-based massively parallel sequencing of formalin-fixed paraffin-embedded DNA by enzymatic depletion of uracil-containing templates.
    Do H; Wong SQ; Li J; Dobrovic A
    Clin Chem; 2013 Sep; 59(9):1376-83. PubMed ID: 23649127
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Validation of a next-generation-sequencing cancer panel for use in the clinical laboratory.
    Simen BB; Yin L; Goswami CP; Davis KO; Bajaj R; Gong JZ; Peiper SC; Johnson ES; Wang ZX
    Arch Pathol Lab Med; 2015 Apr; 139(4):508-17. PubMed ID: 25356985
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Profiling cancer gene mutations in clinical formalin-fixed, paraffin-embedded colorectal tumor specimens using targeted next-generation sequencing.
    Zhang L; Chen L; Sah S; Latham GJ; Patel R; Song Q; Koeppen H; Tam R; Schleifman E; Mashhedi H; Chalasani S; Fu L; Sumiyoshi T; Raja R; Forrest W; Hampton GM; Lackner MR; Hegde P; Jia S
    Oncologist; 2014 Apr; 19(4):336-43. PubMed ID: 24664487
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Using postmortem formalin fixed paraffin-embedded tissues for molecular testing of sudden cardiac death: A cautionary tale of utility and limitations.
    Lin Y; Gryazeva T; Wang D; Zhou B; Um SY; Eng LS; Ruiter K; Rojas L; Williams N; Sampson BA; Tang Y
    Forensic Sci Int; 2020 Mar; 308():110177. PubMed ID: 32155531
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detecting somatic genetic alterations in tumor specimens by exon capture and massively parallel sequencing.
    Won HH; Scott SN; Brannon AR; Shah RH; Berger MF
    J Vis Exp; 2013 Oct; (80):e50710. PubMed ID: 24192750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of Capture and Amplicon-Based Approaches for the Development of a Targeted Next-Generation Sequencing Pipeline to Personalize Lymphoma Management.
    Hung SS; Meissner B; Chavez EA; Ben-Neriah S; Ennishi D; Jones MR; Shulha HP; Chan FC; Boyle M; Kridel R; Gascoyne RD; Mungall AJ; Marra MA; Scott DW; Connors JM; Steidl C
    J Mol Diagn; 2018 Mar; 20(2):203-214. PubMed ID: 29429887
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology.
    Cheng DT; Mitchell TN; Zehir A; Shah RH; Benayed R; Syed A; Chandramohan R; Liu ZY; Won HH; Scott SN; Brannon AR; O'Reilly C; Sadowska J; Casanova J; Yannes A; Hechtman JF; Yao J; Song W; Ross DS; Oultache A; Dogan S; Borsu L; Hameed M; Nafa K; Arcila ME; Ladanyi M; Berger MF
    J Mol Diagn; 2015 May; 17(3):251-64. PubMed ID: 25801821
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The importance of evaluation of DNA amplificability in KRAS mutation testing with dideoxy sequencing using formalin-fixed and paraffin-embedded colorectal cancer tissues.
    Okayama N; Nishioka M; Hazama S; Sakai K; Suehiro Y; Maekawa M; Sakamoto J; Iwamoto S; Kato T; Mishima H; Oka M; Hinoda Y
    Jpn J Clin Oncol; 2011 Feb; 41(2):165-71. PubMed ID: 20926413
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.